Lester, Daniel K.
Burton, Chase
Gardner, Alycia http://orcid.org/0000-0003-2185-5174
Innamarato, Patrick
Kodumudi, Krithika
Liu, Qian
Adhikari, Emma
Ming, Qianqian
Williamson, Daniel B.
Frederick, Dennie T. http://orcid.org/0000-0003-3355-5267
Sharova, Tatyana
White, Michael G. http://orcid.org/0000-0001-5022-5505
Markowitz, Joseph
Cao, Biwei
Nguyen, Jonathan http://orcid.org/0000-0001-6146-2047
Johnson, Joseph
Beatty, Matthew
Mockabee-Macias, Andrea
Mercurio, Matthew
Watson, Gregory
Chen, Pei-Ling
McCarthy, Susan
MoranSegura, Carlos http://orcid.org/0000-0001-8702-0554
Messina, Jane
Thomas, Kerry L.
Darville, Lancia
Izumi, Victoria
Koomen, John M. http://orcid.org/0000-0002-3818-1762
Pilon-Thomas, Shari A.
Ruffell, Brian http://orcid.org/0000-0002-3846-6872
Luca, Vincent C.
Haltiwanger, Robert S. http://orcid.org/0000-0001-7439-9577
Wang, Xuefeng http://orcid.org/0000-0001-5775-408X
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Boland, Genevieve M. http://orcid.org/0000-0002-7522-6173
Lau, Eric K. http://orcid.org/0000-0003-3005-3421
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA172705, R00CA172705, R01CA241559)
Harry J. Lloyd Charitable Trust (Melanoma Research Grant)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM061126)
Article History
Received: 6 July 2022
Accepted: 14 December 2022
First Online: 23 January 2023
Competing interests
: G.M.B. has SRA with Palleon Pharmaceuticals, Olink Proteomics, InterVenn Biosciences and formerly with Takeda Oncology. She consults for Merck and InterVenn. She served on the SAB and a steering committee for Nektar Therapeutics. J. Markowitz has served on an advisory board for Array BioPharma in the past 2 years and has been a PI of grants and funding to his institution from Morphogenesis, Navigate BioPharma, Jackson Laboratory, Microba, Merck, MacroGenics and Reata Pharmaceuticals. The Moffitt Cancer Center has licensed intellectual property related to the proliferation and expansion of tumor-infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Moffitt has also licensed intellectual property to Tuhura Biopharma. S.A.P.-T. is an inventor on such intellectual property. S.A.P.-T. is listed as a co-inventor on a patent application with Provectus Biopharmaceuticals. S.A.P.-T. participates in sponsored research agreements with Provectus Biopharmaceuticals, Iovance Biotherapeutics, Intellia Therapeutics, Dyve Biosciences and Turnstone Biologics that are not related to this research. S.A.P.-T. has received ad hoc consulting fees from Seagen and serves as an advisor for KSQ Therapeutics. The remaining authors declare no competing interests.